株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

非小細胞肺癌治療薬市場 (薬剤クラス別) -世界の業界分析、規模、シェア、成長、動向、および2015〜2023年の予測

Non Small Cell Lung Cancer Therapeutics Market By Drug Class - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

発行 Transparency Market Research 商品コード 347760
出版日 ページ情報 英文 94 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
非小細胞肺癌治療薬市場 (薬剤クラス別) -世界の業界分析、規模、シェア、成長、動向、および2015〜2023年の予測 Non Small Cell Lung Cancer Therapeutics Market By Drug Class - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023
出版日: 2015年11月26日 ページ情報: 英文 94 Pages
概要

レポートでは、非小細胞肺癌治療薬市場について調査し、市場の動向と今後の見通し、市場の機会などのほか、薬剤クラス別、地域別動向、および参入する主要企業のプロファイルなどをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 業界分析

  • イントロダクション
  • 治療ガイドラインと疾患管理
  • コンパニオン診断:概要
  • 法規制シナリオ
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
  • イベント影響分析
  • 市場の魅力度分析
  • 競合環境

第4章 市場セグメンテーション:薬剤別

  • 概要
  • 世界の非小細胞肺癌市場収益:薬剤クラス別
    • 血管形成阻害剤
    • EGFRブロッカー
    • キナーゼ阻害剤
    • 微小管安定剤
    • 葉酸代謝拮抗剤
    • PD-1/PD-L1阻害剤

第5章 パイプライン分析

  • 概要
  • 後期 (第3相)
  • 早期 (第1相、第2相) (定性分析)

第6章 地域別市場

  • イントロダクション
  • 世界市場収益
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第7章 提言

  • 市場に普及させるための研究開発イニシアティブ
  • 新興市場に対する投資

第8章 企業プロファイル

  • Astra Zeneca PLC
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Eli Lilly & Co.
  • Pfizer, Inc.
  • Genentech, Inc. (a Roche company)
  • Sun Pharmaceutical Industries Ltd.
目次

This report on the non-small cell lung cancer (NSCLC) Therapeutics market studies the current and future prospects of the global market. Non-small cell lung cancer is a type of lung cancer which accounted 85-90% of all lung cancers. There are three major subtypes of NSCLC namely squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC is relatively insensitive to chemotherapy compared to small cell lung cancer. Increasing awareness along with incidence rate are expected to propel the global non-small cell lung cancer therapeutics market.

The NSCLC market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global NSCLC therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global NSCLC therapeutics market.

Based on drug class, the NSCLC therapeutics market has been segmented into six major categories: angiogenesis inhibitor, epidermal growth factor receptor blocker, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/ PD-L1 inhibitor. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the global NSCLC therapeutics market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, China, and Rest of Asia Pacific), and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global NSCLC therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, Astra Zeneca plc, and Celgene Corporation.

The global non-small cell lung cancer therapeutics market is segmented as follows:

Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013-2023 (US$ Mn)

  • Overview
  • Angiogenesis Inhibitor
    • Avastin (bevacizumab)
    • Cyramza (Ramucirumab)
  • Epidermal Growth Factor Receptor Blocker
    • Tarceva (erlotinib)
    • Gilotrif (afatinib)
    • Iressa (gefitinib)
  • Kinase Inhibitor
    • Xalkori (crizotinib)
    • Zykadia (ceritinib)
  • Microtubule Stabilizer
    • Abraxane (paclitaxel protein bound)
    • Docetaxel
  • Folate Antimetabolites
    • Alimta (pemetrexed)
  • PD-1/ PD-L1 Inhibitor
    • Opdivo (nivolumab)
    • Keytruda (pembrolizumab)

Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics Market

  • Overview
  • Late Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)
    • Avelumab - Pfizer, Inc.
    • MPDL3280A - Roche
    • MEDI4736 - AstraZeneca
    • Abemaciclib - Eli Lilly and Company
    • Others
  • Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)

Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013-2023 (US$ Mn)

  • Overview
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Rest of the World

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Market Segmentation

2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Comparative Analysis: Non-Small Cell Lung Cancer Market, by Geography, 2014 & 2023 (Value %)

3. Non-Small Cell Lung Cancer Market Overview

  • 3.1. Introduction
  • 3.2. Treatment Guidelines and Disease Management
  • 3.3. Companion Diagnostics: Overview
  • 3.4. Regulatory Scenario
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities
  • 3.6. Event Impact Analysis, 2013 - 2023
  • 3.7. Market Attractiveness Analysis of Global Non-Small Cell Lung Cancer Market, by Geography, 2014
  • 3.8. Competitive Landscape
    • 3.8.1. Market Share Analysis of Key Players, 2014 (Value %)

4. Market Segmentation - By Drug

  • 4.1. Overview
  • 4.2. Global Non-Small Cell Lung Cancer Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
    • 4.2.1. Global Angiogenesis Inhibitor Market Revenue, 2013-2023 (US$ Mn) and Analysis
    • 4.2.2. Global EGFR Blockers Market Revenue, 2013-2023 (US$ Mn) and Analysis
    • 4.2.3. Global Kinase Inhibitor Market Revenue, 2013-2023 (US$ Mn) and Analysis
    • 4.2.4. Global Microtubule Stabilizer Market Revenue, 2013-2023 (US$ Mn) and Analysis
    • 4.2.5. Global Folate Antimetabolites Market Revenue, 2013-2023 (US$ Mn) and Analysis
    • 4.2.6. Global PD-1/PD-L1 Inhibitor Market Revenue, 2013-2023 (US$ Mn) and Analysis

5. Pipeline Analysis

  • 5.1. Overview
  • 5.2. Late Stage (Phase III)
    • 5.2.1. Avelumab - Pfizer, Inc.
    • 5.2.2. MPDL3280A - Roche
    • 5.2.3. MEDI4736 - AstraZeneca
    • 5.2.4. Abemaciclib - Eli Lilly and Company
    • 5.2.5. Others
  • 5.3. Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)

6. Market Segmentation - By Geography

  • 6.1. Introduction
  • 6.2. Global Non-Small Cell Lung Cancer Market Revenue, by Region, 2013-2023 (US$ Mn)
  • 6.3. North America Non-Small Cell Lung Cancer Market Revenue, by Country, 2013-2023 (US$ Mn)
    • 6.3.1. U.S. Non-Small Cell Lung Cancer Market Revenue, 2013-2023, (US$ Mn)
    • 6.3.2. Canada Non-Small Cell Lung Cancer Market Revenue, 2013-2023, (US$ Mn)
  • 6.4. Europe Non-Small Cell Lung Cancer Market - Revenue, by Country, 2013-2023 (US$ Mn)
    • 6.4.1. U.K. Non-Small Cell Lung Cancer Market Revenue, 2013-2023, (US$ Mn)
    • 6.4.2. Germany Non-Small Cell Lung Cancer Market Revenue, 2013-2023, (US$ Mn)
    • 6.4.3. Rest of Europe Non-Small Cell Lung Cancer Market Revenue, 2013-2023, (US$ Mn)
  • 6.5. Asia Pacific Non-Small Cell Lung Cancer Market Revenue, by Country, 2013-2023 (US$ Mn)
    • 6.5.1. Japan Non-Small Cell Lung Cancer Market Revenue, 2013-2023, (US$ Mn)
    • 6.5.2. China Non-Small Cell Lung Cancer Market Revenue, 2013-2023, (US$ Mn)
    • 6.5.3. Rest of APAC Non-Small Cell Lung Cancer Market Revenue, 2013-2023, (US$ Mn)
  • 6.6. Rest of the World Non-Small Cell Lung Cancer Market Revenue, by Country, 2013-2023 (US$ Mn)

7. Recommendations

  • 7.1. Recommendation 1: Research and Development Initiatives to Penetrate the Market
  • 7.2. Recommendation 2: Investment in Emerging Economy

8. Company Profiles

  • 8.1. Astra Zeneca PLC
  • 8.2. Boehringer Ingelheim
  • 8.3. Bristol-Myers Squibb
  • 8.4. Celgene Corporation
  • 8.5. GlaxoSmithKline PLC
  • 8.6. Eli Lilly & Co.
  • 8.7. Pfizer, Inc.
  • 8.8. Genentech, Inc. (a Roche company)
  • 8.9. Sun Pharmaceutical Industries Ltd.
Back to Top